Lynx1 Capital Management LP
Lynx1 Capital Management LP reported 27 holdings worth US$866M as of Jun 30, 2026 (Form 13F/A)
As of Jun 30, 2026 · Filed Aug 13, 2026
Lynx1 Capital Management LP reported 27 holdings worth US$866M as of Jun 30, 2026. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and Agios Pharmaceuticals, Inc. Filed Aug 13, 2026 (Form 13F/A).
- Holdings
- 27
- Value as reported
- US$866M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cullinan Therapeutics, Inc. | 8.96M | US$163M | 18.9% |
| Stoke Therapeutics, Inc. | 4.04M | US$132M | 15.3% |
| Agios Pharmaceuticals, Inc. | 3.41M | US$127M | 14.6% |
| C4 Therapeutics, Inc. | 7.33M | US$34.2M | 4.0% |
| Korro Bio, Inc. | 1.54M | US$20.3M | 2.3% |
| Tscan Therapeutics, Inc. | 8.02M | US$7.86M | 0.91% |
| Precision Biosciences, Inc. | 950K | US$7.47M | 0.86% |
| Neuphoria Therapeutics Inc. | 875K | US$3.83M | 0.44% |
| Passage Bio, Inc. | 674K | US$3.29M | 0.38% |
| Cg Oncology, Inc. | 31,391 | US$2.23M | 0.26% |
| Pliant Therapeutics, Inc. | 1.8M | US$2.05M | 0.24% |
| Entrada Therapeutics, Inc. | 179K | US$1.31M | 0.15% |
| Vyne Therapeutics Inc. | 1.63M | US$1.06M | 0.12% |
| Traws Pharma, Inc. | 559K | US$472K | 0.05% |
| Foghorn Therapeutics Inc. | 61,588 | US$301K | 0.03% |
| Denali Therapeutics Inc. | 11,658 | US$300K | 0.03% |
| Xencor, Inc. | 18,194 | US$293K | 0.03% |
| Absci Corporation | 21,245 | US$246K | 0.03% |
| Werewolf Therapeutics, Inc. | 658K | US$237K | 0.03% |
| Avalo Therapeutics, Inc. | 10,100 | US$187K | 0.02% |
| Bolt Biotherapeutics, Inc. | 30,800 | US$119K | 0.01% |
| Nuvation Bio Inc. | 16,029 | US$91,045 | 0.01% |
| Eupraxia Pharmaceuticals, Inc. | 10,000 | US$66,100 | <0.01% |
| Inhibikase Therapeutics, Inc. | 20,000 | US$40,600 | <0.01% |
| Design Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ibio, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related